drugset / Trial / NCT02256774

Study of Pharmacokinetic Interaction Between Combivir® (ZDV+3TC) and BILR 355 BS Plus Ritonavir in Healthy Subjects

NCT02256774 ↗

Phase 1 Completed 51 enrolled Boehringer Ingelheim
RandomizedParallel-groupOpen-labelTreatment

Summary

Study to determine the effect of BILR 355/r on Combivir® pharmacokinetics and the effect of Combivir® on BILR 355 BS pharmacokinetics.

Timeline

Start
2004-10
Primary completion
2005-05
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject BILR 355 BS Unknown — —
Subject Lamivudine Other / unclassified — —
Subject ZDV Unknown — —
Background Ritonavir Other / unclassified — —

Indications

No indication recorded.